Literature DB >> 24510676

Preparation and use of reverse protein microarrays.

Elisa Pin1,2, Giulia Federici1,3, Emanuel F Petricoin1.   

Abstract

Reverse-phase protein array (RPPA) is a multiplex, high-throughput proteomic technique for profiling the activation status of signal transduction pathways involved in cancer survival and progression, potentially allowing for identification of new biomarkers and drug targets. On RPPA, the entire patient proteome is immobilized on a spot and single proteins can be quantified across a set of samples, spotted on the same array, with high specificity and sensitivity. Array immunostaining and signal amplification systems are used to generate a signal proportional to the concentration of the analyte. Dedicated scanners and software are used to detect spots, measure intensity, subtract background, normalize signal, and generate a numeric value as output. The generated output file is then analyzed using several different bioinformatic and biostatistical tools. In this unit, the RPPA procedure is described in depth, from sample handling and preparation to data analysis, with particular emphasis on tissue sample analysis.
Copyright © 2014 John Wiley & Sons, Inc.

Entities:  

Keywords:  analysis; antibody; cells; microarray; protein; tissues

Mesh:

Substances:

Year:  2014        PMID: 24510676     DOI: 10.1002/0471140864.ps2707s75

Source DB:  PubMed          Journal:  Curr Protoc Protein Sci        ISSN: 1934-3655


  24 in total

1.  A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray.

Authors:  Elisa Pin; Steven Stratton; Claudio Belluco; Lance Liotta; Ray Nagle; K Alex Hodge; Jianghong Deng; Ting Dong; Elisa Baldelli; Emanuel Petricoin; Mariaelena Pierobon
Journal:  Mol Oncol       Date:  2016-10-14       Impact factor: 6.603

2.  Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.

Authors:  Mariaelena Pierobon; Corinne Ramos; Shukmei Wong; K Alex Hodge; Jessica Aldrich; Sara Byron; Stephen P Anthony; Nicholas J Robert; Donald W Northfelt; Mohammad Jahanzeb; Linda Vocila; Julia Wulfkuhle; Guido Gambara; Rosa I Gallagher; Bryant Dunetz; Nicholas Hoke; Ting Dong; David W Craig; Massimo Cristofanilli; Brian Leyland-Jones; Lance A Liotta; Joyce A O'Shaughnessy; John D Carpten; Emanuel F Petricoin
Journal:  Clin Cancer Res       Date:  2017-04-26       Impact factor: 12.531

3.  Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development.

Authors:  Kristine E Brown; Gustavo Chagoya; Shawn G Kwatra; Timothy Yen; Stephen T Keir; Mary Cooter; Katherine A Hoadley; Ahmed Rasheed; Eric S Lipp; Roger Mclendon; Francis Ali-Osman; Darell D Bigner; John H Sampson; Madan M Kwatra
Journal:  J Neurochem       Date:  2015-02-12       Impact factor: 5.372

Review 4.  Reverse phase protein arrays: mapping the path towards personalized medicine.

Authors:  Rosa I Gallagher; Virginia Espina
Journal:  Mol Diagn Ther       Date:  2014-12       Impact factor: 4.074

5.  Patient-derived xenografts of central nervous system metastasis reveal expansion of aggressive minor clones.

Authors:  Ben Yi Tew; Christophe Legendre; Mark A Schroeder; Tim Triche; Gerald C Gooden; Yizhou Huang; Loren Butry; Daniel J Ma; Kyle Johnson; Rae Anne Martinez; Mariaelena Pierobon; Emanuel F Petricoin; Joyce O'shaughnessy; Cindy Osborne; Coya Tapia; David N Buckley; Jennifer Glen; Mark Bernstein; Jann N Sarkaria; Steven A Toms; Bodour Salhia
Journal:  Neuro Oncol       Date:  2020-01-11       Impact factor: 12.300

6.  Functional and biological heterogeneity of KRASQ61 mutations.

Authors:  Minh V Huynh; G Aaron Hobbs; Antje Schaefer; Mariaelena Pierobon; Leiah M Carey; J Nathaniel Diehl; Jonathan M DeLiberty; Ryan D Thurman; Adelaide R Cooke; Craig M Goodwin; Joshua H Cook; Lin Lin; Andrew M Waters; Naim U Rashid; Emanuel F Petricoin; Sharon L Campbell; Kevin M Haigis; Diane M Simeone; Costas A Lyssiotis; Adrienne D Cox; Channing J Der
Journal:  Sci Signal       Date:  2022-08-09       Impact factor: 9.517

7.  Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer.

Authors:  G Aaron Hobbs; Nicole M Baker; Anne M Miermont; Ryan D Thurman; Mariaelena Pierobon; Timothy H Tran; Andrew O Anderson; Andrew M Waters; J Nathaniel Diehl; Bjoern Papke; Richard G Hodge; Jennifer E Klomp; Craig M Goodwin; Jonathan M DeLiberty; Junning Wang; Raymond W S Ng; Prson Gautam; Kirsten L Bryant; Dominic Esposito; Sharon L Campbell; Emanuel F Petricoin; Dhirendra K Simanshu; Andrew J Aguirre; Brian M Wolpin; Krister Wennerberg; Udo Rudloff; Adrienne D Cox; Channing J Der
Journal:  Cancer Discov       Date:  2019-10-24       Impact factor: 38.272

8.  Neratinib-Plus-Cetuximab in Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study.

Authors:  Samuel A Jacobs; James J Lee; Thomas J George; James L Wade; Philip J Stella; Ding Wang; Ashwin R Sama; Fanny Piette; Katherine L Pogue-Geile; Rim S Kim; Patrick G Gavin; Corey Lipchik; Huichen Feng; Ying Wang; Melanie Finnigan; Brian F Kiesel; Jan H Beumer; Norman Wolmark; Peter C Lucas; Carmen J Allegra; Ashok Srinivasan
Journal:  Clin Cancer Res       Date:  2020-11-17       Impact factor: 12.531

9.  Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti-PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer.

Authors:  Paula I Gonzalez-Ericsson; Julia D Wulfkhule; Rosa I Gallagher; Xiaopeng Sun; Margaret L Axelrod; Quanhu Sheng; Na Luo; Henry Gomez; Violeta Sanchez; Melinda Sanders; Lajos Pusztai; Emanuel Petricoin; Kim R M Blenman; Justin M Balko
Journal:  Clin Cancer Res       Date:  2021-10-01       Impact factor: 12.531

10.  Integrated multi-omics analyses on patient-derived CRC organoids highlight altered molecular pathways in colorectal cancer progression involving PTEN.

Authors:  Marta Codrich; Emiliano Dalla; Catia Mio; Giulia Antoniali; Matilde Clarissa Malfatti; Stefania Marzinotto; Mariaelena Pierobon; Elisa Baldelli; Carla Di Loreto; Giuseppe Damante; Giovanni Terrosu; Carlo Ennio Michele Pucillo; Gianluca Tell
Journal:  J Exp Clin Cancer Res       Date:  2021-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.